Last reviewed · How we verify
Atazanavir (Week 24 switch)
Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication.
Atazanavir is a protease inhibitor that blocks HIV protease, preventing the cleavage of viral polyproteins and stopping HIV replication. Used for HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy).
At a glance
| Generic name | Atazanavir (Week 24 switch) |
|---|---|
| Also known as | Reyataz |
| Sponsor | Bristol-Myers Squibb |
| Drug class | HIV protease inhibitor |
| Target | HIV protease |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Atazanavir binds to the active site of HIV protease, an enzyme essential for processing viral precursor proteins into mature, functional viral components. By inhibiting this protease, the drug prevents the formation of infectious viral particles, thereby reducing viral load and slowing disease progression. It is typically used as part of combination antiretroviral therapy (cART) in HIV-infected patients.
Approved indications
- HIV-1 infection in treatment-experienced and treatment-naïve adults (as part of combination antiretroviral therapy)
Common side effects
- Hyperbilirubinemia
- Jaundice
- Nausea
- Diarrhea
- Headache
- Rash
- Nephrolithiasis
Key clinical trials
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) (PHASE3)
- A Study of a Nucleoside Sparing Regimen in HIV-1 Infected Patients With Detectable Viremia (PHASE2)
- Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants (PHASE3)
- Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults (PHASE3)
- Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r (PHASE4)
- Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor (PI) and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to a Fixed-dose Tablet Containing Emtricitabine/Rilpivirine/Tenofovir DF (PHASE3)
- Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir (Week 24 switch) CI brief — competitive landscape report
- Atazanavir (Week 24 switch) updates RSS · CI watch RSS
- Bristol-Myers Squibb portfolio CI